Madrigal Pharmaceuticals received FDA approval for its drug Rezdiffra, which targets MASH. The company also participated in a conference hosted by Morgan Stanley.
11 reports, 4 independent
Updated Oct 20
Gone quiet
Reached 3 outlets in its first 24 hours
- Reports
- 11
- Developments
- 2
- Repetition
- 82%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Madrigal Pharmaceuticals received FDA approval for its drug Rezdiffra, which targets MASH. The company also participated in a conference hosted by Morgan Stanley.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Rezdiffra approved by FDA for MASH; company also attended Morgan Stanley conference.1 source
USPTO granted Notice of Allowance for Rezdiffra, a drug developed by Madrigal for MASH.1 source
Keep exploring
The entities involved
-
Madrigal Pharmaceuticals (United States)
company in West Conshohocken, United States
Nothing else this week.
- FDA
-
Mash
Japanese singer-songwriter
Nothing else this week.
Related events
Coverage
Newest first; wire copies grouped- manilatimes.net
- GlobeNewswireMadrigal Pharmaceuticals to Participate in Morgan Stanley 23rd Annual Global Healthcare Conference CONSHOHOCKEN, Pa., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
- GlobeNewswireMadrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) CONSHOHOCKEN, Pa., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL),
- GlobeNewswireMadrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference CONSHOHOCKEN, Pa., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today
- GlobeNewswireMadrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) CONSHOHOCKEN, Pa., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL),
- Insider MonkeyMadrigal Pharmaceuticals, Inc. (MDGL)’s Rezdiffra Hits 51% Liver Stiffness Reduction in Phase 3 We recently compiled a list of 10 Most Undervalued Healthcare Stocks to Buy According to Analysts. Madr
- GlobeNewswireMadrigal Pharmaceuticals to Release Second-Quarter 2025 Financial Results and Host Webcast on August 5, 2025 CONSHOHOCKEN, Pa., July 25, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDA
- Insider MonkeyMadrigal (MDGL) Secures $500M to Fuel MASH Pipeline Expansion Madrigal Pharmaceuticals (NASDAQ:MDGL) is one of the best biotech stocks to buy according to billionaire Steve Cohen. On July 22, MDGL an
- ZacksMDGL Stock Soars 11% on New Patent Protecting Rezdiffra Dosing Rights Madrigal Pharmaceuticals MDGL shares soared 10.9% on Wednesday. The uptrend was observed after the U.S. Patent and Trademark Offi
- GlobeNewswireMadrigal Pharmaceuticals Receives Notice of Allowance from U.S. Patent and Trademark Office for New U.S. Patent Covering Rezdiffra™ (Resmetirom) • Provides Protection Through Sept. 2044; Will Be List